Oppenheimer Cuts Mediwound (NASDAQ:MDWD) Price Target to $7.00

Mediwound (NASDAQ:MDWD) had its price target dropped by investment analysts at Oppenheimer from $15.00 to $7.00 in a research note issued to investors on Wednesday, The Fly reports. The brokerage presently has an “outperform” rating on the biopharmaceutical company’s stock. Oppenheimer’s price target would suggest a potential upside of 132.56% from the company’s current price.

A number of other equities analysts also recently issued reports on the stock. ValuEngine upgraded shares of Mediwound from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. HC Wainwright began coverage on shares of Mediwound in a research note on Monday, August 5th. They set a “buy” rating and a $5.50 price objective on the stock. Finally, Zacks Investment Research upgraded shares of Mediwound from a “sell” rating to a “hold” rating in a research note on Friday, July 12th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Mediwound presently has an average rating of “Buy” and an average price target of $7.25.

MDWD stock traded down $0.16 during mid-day trading on Wednesday, reaching $3.01. The company had a trading volume of 38,900 shares, compared to its average volume of 190,528. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.99 and a quick ratio of 3.79. The stock has a market cap of $86.70 million, a P/E ratio of -6.14 and a beta of 0.49. The business has a 50 day moving average of $3.24. Mediwound has a 12 month low of $2.55 and a 12 month high of $6.75.

Mediwound (NASDAQ:MDWD) last issued its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.12) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.15) by $0.03. Mediwound had a negative net margin of 18.43% and a negative return on equity of 383.19%. The business had revenue of $20.75 million for the quarter, compared to the consensus estimate of $7.03 million. Equities analysts anticipate that Mediwound will post -0.59 EPS for the current fiscal year.

A number of large investors have recently bought and sold shares of MDWD. Meitav Dash Investments Ltd. raised its holdings in shares of Mediwound by 0.6% in the first quarter. Meitav Dash Investments Ltd. now owns 598,508 shares of the biopharmaceutical company’s stock worth $2,993,000 after buying an additional 3,536 shares during the last quarter. ARK Investment Management LLC purchased a new position in shares of Mediwound during the second quarter worth $325,000. Millennium Management LLC raised its holdings in shares of Mediwound by 33.2% during the fourth quarter. Millennium Management LLC now owns 68,365 shares of the biopharmaceutical company’s stock worth $278,000 after purchasing an additional 17,048 shares during the last quarter. Menta Capital LLC raised its holdings in shares of Mediwound by 200.2% during the first quarter. Menta Capital LLC now owns 44,514 shares of the biopharmaceutical company’s stock worth $223,000 after purchasing an additional 29,686 shares during the last quarter. Finally, Oppenheimer & Co. Inc. raised its holdings in shares of Mediwound by 33.5% during the second quarter. Oppenheimer & Co. Inc. now owns 43,800 shares of the biopharmaceutical company’s stock worth $148,000 after purchasing an additional 11,000 shares during the last quarter. 31.16% of the stock is owned by institutional investors.

About Mediwound

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.

Further Reading: What is the market perform rating?

The Fly

Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply